Nervous System News and Research

Latest Nervous System News and Research

Omeros presents clinical data of OMS302 on reducing pupil constriction during ILR at ASCRS meeting

Omeros Corporation today reported analyses of Phase 2 and Phase 3 clinical data showing the favorable impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement.

25 Apr 2013

ORAEs increase costs of care, hospital stays and risks of readmission and mortality, research finds

Pacira Pharmaceuticals, Inc. today announced the publication of findings from a retrospective analysis of more than 37,000 patients who underwent common inpatient surgeries at a large, 26-hospital healthcare system and received opioids for postsurgical pain management.

25 Apr 2013

Individual hydroxymethylcytosine molecules in DNA detected by new method involving chemical modification and nanopore analysis

Changes in the bases that make up DNA act as markers, telling a cell which genes it should read and which it shouldn’t. In the journal Angewandte Chemie, a British team has now introduced a new method that makes it possible to enrich the rare gene segments that contain the modified base hydroxymethylcytosine and to identify individual hydroxymethylcytosine molecules in DNA. Such modifications are associated with autoimmune diseases and cancer.

24 Apr 2013

Researchers develop sensor system to assess how blasts impact human body

Improvised explosive devices are becoming a global problem for the U.S. armed forces. To prevent injuries to soldiers and provide better care to those who are injured, the U.S. military is striving to better understand how blasts impact the human body.

24 Apr 2013

Methodist Hospital will soon have new brain and pituitary tumor treatment center

Brain and pituitary tumor patients will soon have access to a state-of-the-art facility at The Methodist Hospital, a result of a $10 million dollar commitment from a Houston oil executive.

24 Apr 2013

Investigational treatment for ALS passes early phase clinical trial for safety

An investigational treatment for an inherited form of Lou Gehrig's disease has passed an early phase clinical trial for safety, researchers at Washington University School of Medicine in St. Louis and Massachusetts General Hospital report.

24 Apr 2013

BD receives FDA approval for second prefilled injectable drug

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.

From BD (Becton, Dickinson and Company) 24 Apr 2013

Researchers uncover potential new way to fight obesity-related illness

A potential new way to fight obesity-related illness has been uncovered, thanks to serendipitous research led by investigators at the Case Western Reserve University School of Medicine.

24 Apr 2013

Animal models of Huntington's disease allow better insights into disease's genetics

Scientific progress in Huntington's disease (HD) relies upon the availability of appropriate animal models that enable insights into the disease's genetics and/or pathophysiology.

23 Apr 2013

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

22 Apr 2013

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights from Merck, known as MSD outside the United States and Canada, to develop and commercialize MK-0657, a small molecule NMDA receptor subunit 2B (NR2B) antagonist for all human indications, including depression.

22 Apr 2013

Advanced microscope reveals process where mutations lead to autism and other diseases

Using spinning disk microscopy on barely day-old zebra fish embryos, University of Oregon scientists have gained a new window on how synapse-building components move to worksites in the central nervous system.

22 Apr 2013

CI therapy appears to benefit children with cerebral palsy

Researchers at the University of Alabama at Birmingham (UAB) report that children with cerebral palsy who underwent Constraint Induced Movement therapy (CI therapy) saw a significant increase in grey matter volume in areas of the brain associated with movement.

22 Apr 2013

Sleep related breathing disorders associated with cognitive and behavioral impairment in children

People lobbying for gun control may want to consider another culprit in the post-Newtown search for the answer to our unfathomable questions.

22 Apr 2013

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.

20 Apr 2013

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, today announced positive topline results from a Phase 2 clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa).

20 Apr 2013

Researchers map use of alternative treatment among multiple sclerosis patients

A major Nordic research project involving researchers from the University of Copenhagen has, for the first time ever, mapped the use of alternative treatment among multiple sclerosis patients - knowledge which is important for patients with chronic disease and the way in which society meets them.

19 Apr 2013

Research shows infants experience automatic calming reaction when carried by their mothers

There is a very good reason mothers often carry their crying babies, pacing the floor, to help them calm down. New research published in the Cell Press journal Current Biology on April 18 shows that infants experience an automatic calming reaction upon being carried, whether they are mouse or human babies.

19 Apr 2013

Targacept moving forward with Phase 2b study of TC-5619 for treatment of schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in the Phase 2b study of TC-5619 as a treatment for negative symptoms and cognitive dysfunction in schizophrenia.

19 Apr 2013

Excess glutamate drives schizophrenia in high-risk individuals

An excess of the brain neurotransmitter glutamate may cause a transition to psychosis in people who are at risk for schizophrenia, reports a study from investigators at Columbia University Medical Center published in the current issue of Neuron.

19 Apr 2013

Nervous System News and Research

Latest Nervous System News and Research

Omeros presents clinical data of OMS302 on reducing pupil constriction during ILR at ASCRS meeting

ORAEs increase costs of care, hospital stays and risks of readmission and mortality, research finds

Individual hydroxymethylcytosine molecules in DNA detected by new method involving chemical modification and nanopore analysis

Researchers develop sensor system to assess how blasts impact human body

Methodist Hospital will soon have new brain and pituitary tumor treatment center

Investigational treatment for ALS passes early phase clinical trial for safety

BD receives FDA approval for second prefilled injectable drug

Researchers uncover potential new way to fight obesity-related illness

Animal models of Huntington's disease allow better insights into disease's genetics

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Advanced microscope reveals process where mutations lead to autism and other diseases

CI therapy appears to benefit children with cerebral palsy

Sleep related breathing disorders associated with cognitive and behavioral impairment in children

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

Researchers map use of alternative treatment among multiple sclerosis patients

Research shows infants experience automatic calming reaction when carried by their mothers

Targacept moving forward with Phase 2b study of TC-5619 for treatment of schizophrenia

Excess glutamate drives schizophrenia in high-risk individuals

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Nervous System News and Research

Latest Nervous System News and Research

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Newsletters you may be interested in